Save billions or stick with Humira? Drug brokers steer Ameri

Humira has enjoyed high-priced U.S. exclusivity for 20 years. Its challengers could save the health care system $9 billion and herald savings from the whole class of drugs called biosimilars.

Related Keywords

United Kingdom , Brooklyn , Kentucky , United States , Poland , Tennessee , New York , Denmark , California , Americans , American , Greg Baker , Michael Thompson , Antonio Ciaccia , Mark Cuban , Madelaine Feldman , Coherus Biosciences , Paul Holmes , Keith Athow , Alex Jung , Rachel Shubert , Cora Opsahl , Siddharth Singh , Kaiser Permanente , Mary Beth Lang , Richard Gonzalez , Kevin Ali , Juliana Reed , Kroger , American College Of Rheumatology , American Gastroenterological Association , National Alliance Of Healthcare Purchaser Coalitions , Health News , Midwest Business Group On Health , Service Employees International Union , Bj Health Fund , Biosimilars Forum , Arthur Allen , Williams Barber Morel , Express Scripts , Federal Trade Commission , Blue Shield , Cost Plus Drugs , Sue Lee , National Alliance , Healthcare Purchaser , Midwest Business Group , Marcus Snow , American College , New Orleans , Gastroenterological Association , Inflation Reduction Act , Rich Lieblich ,